Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4957452 | 0.94 | TK1 (0.58) | TK1 | |
| SCHEMBL6379327 | 0.92 | TK1 (0.67) | TK1DHFR | |
| SCHEMBL316663 | 0.90 | TK1 (0.65) | TK1DHFR | |
| SCHEMBL27054363 | 0.90 | TK1 (0.65) | TK1DHFR | |
| SCHEMBL7537554 | 0.90 | TK1 (0.65) | TK1DHFR | |
| SCHEMBL24420522 | 0.90 | TK1 (0.65) | TK1DHFR | |
| SCHEMBL19308099 | 0.90 | TK1 (0.65) | TK1DHFR | |
| SCHEMBL3272720 | 0.89 | TK1 (0.63) | TK1DHFR | |
| SCHEMBL4542151 | 0.89 | TK1 (0.63) | TK1DHFR | |
| SCHEMBL2295 | 0.89 | TK1 (0.63) | TK1DHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6995248-B2 | Immobilization of nucleic acids | DR. CHIP BIOTECHNOLOGY, INC. (TW) | 2006-02-07 | — | — | US | claimed |
| US-20020177695-A1 | Nucleic acid probes and methods | DUKE UNIVERSITY | 2002-11-28 | — | — | US | claimed |
| US-6288221-B1 | REPLACING NUCLEOSIDE WITH DIMETHOXYTRITYL, PHOSPHORAMIDITE, OR HALONUCLEOSIDE DERIVATIVE; ELECTROCHEMICAL OR PHOTOCHEMICAL DETECTION OF NUCLEIC ACID SEQUENCES | DUKE UNIVERSITY | 2001-09-11 | — | — | US | claimed |
| US-12584168-B2 | Sample preparation method | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-03-24 | — | — | US | disclosed |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | OPENTRONS LABWORKS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250313889-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2025-10-09 | — | — | US | disclosed |
| CN-117343990-B | Method and kit for determining target polynucleotide and probe set | 牛津纳米孔科技公开有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-118957041-A | Method for determining polymer sequences | 牛津纳米孔科技公开有限公司 | 2024-11-15 | — | — | CN | disclosed |
| CN-112703256-B | Method for determining polymer sequences | 牛津纳米孔科技公开有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-20240117337-A1 | METHODS AND POLYNUCLEOTIDES FOR AMPLIFYING A TARGET POLYNUCLEOTIDE | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2024-04-11 | — | — | US | disclosed |
| US-20240076719-A9 | METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2024-03-07 | — | — | US | disclosed |
| EP-0766691-B1 | HYDROXYALKYLAMMONIUM-PYRIMIDINES OR PURINES AND NUCLEOSIDE DERIVATIVES, USEFUL AS INHIBITORS OF INFLAMMATORY CYTOKINES | MACRONEX INC (US) | 1999-11-10 | — | — | EP | disclosed |
| US-5679684-A | INTIINFLAMMATORY AGENTS, ANTIARTHRITIS AGENTS, NERVOUS SYSTEM DISORDERS, AIDS | MACRONEX, INC. (US) | 1997-10-21 | — | — | US | disclosed |
| US-5677439-A | PREVENTION GENE EXPRESSION | SANOFI (FR) | 1997-10-14 | — | — | US | disclosed |
| EP-0766691-A1 | HYDROXYALKYLAMMONIUM-PYRIMIDINES OR PURINES AND NUCLEOSIDE DERIVATIVES, USEFUL AS INHIBITORS OF INFLAMMATORY CYTOKINES | MACRONEX, INC. (US) | 1997-04-09 | — | — | EP | disclosed |
| US-5550132-A | TREATING SEPTIC SHOCK, CACHEXIA, RHEUMATOID ARTHRITIS, INFLAMMATORY BOWEL DISEASE, MULTIPLE SCLEROSIS, AIDS | UNIVERSITY OF NORTH CAROLINA (US) | 1996-08-27 | — | — | US | disclosed |
| WO-1995035304-A1 | HYDROXYALKYLAMMONIUM-PYRIMIDINES OR PURINES AND NUCLEOSIDE DERIVATIVES, USEFUL AS INHIBITORS OF INFLAMMATORY CYTOKINES | MACRONEX, INC. (US) | 1995-12-28 | — | — | WO | disclosed |
| EP-0541722-B1 | COMPOUNDS AND METHODS FOR INHIBITING GENE EXPRESSION | STERLING WINTHROP INC (US) | 1995-12-20 | — | — | EP | disclosed |
| EP-0541722-A1 | COMPOUNDS AND METHODS FOR INHIBITING GENE EXPRESSION. | STERLING WINTHROP INC (US) | 1993-05-19 | — | — | EP | disclosed |
| WO-1992002534-A2 | COMPOUNDS AND METHODS FOR INHIBITING GENE EXPRESSION | STERLING DRUG, INC. (US) | 1992-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584168-B2 | Sample preparation method | POLN, POLRMT, POLM | TK1 472/4885DHFR 2012/4885 |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | POLRMT, POLL, SARS1 | TK1 1713/4885DHFR 2190/4885 |
| US-20020177695-A1 | Nucleic acid probes and methods | NUDT1, NT5C3B, NT5C2 | TK1 71/4885DHFR 208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.